August 9, 2023 05:42 PM EDTUpdated August 10, 11:48 AM
R&D

Il­lu­mi­na slash­es out­look for 2023, two ex­ec­u­tives de­part

Jared Whitlock

Features Editor

Il­lu­mi­na, the world’s largest DNA se­quenc­ing com­pa­ny, cut its sales fore­cast for 2023 as de­mand slumped in Chi­na, and al­so an­nounced that two ex­ec­u­tives will …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times